cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Exelixis Inc
18 own
36 watching
Current Price
$17.55
$-0.06
(-0.34%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
5,660.59M
52-Week High
52-Week High
23.4
52-Week Low
52-Week Low
14.87
Average Volume
Average Volume
1.88M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
37.9484
iconMarket Capitalization5,660.59M
icon52-Week High23.4
icon52-Week Low14.87
iconAverage Volume1.88M
iconDividend Yield--
iconP/E Ratio37.9484
What does the Exelixis Inc do?
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Read More
How much money does Exelixis Inc make?
News & Events about Exelixis Inc.
Zolmax
14days ago
Exelixis (NASDAQ:EXEL Get Rating) had its target price cut by JMP Securities from $25.00 to $24.00 in a research note published on Thursday, Benzinga reports. They currently have a market outperform rating on the biotechnology companys stock. A number of other brokerages have also recently weighed ...
Benzinga
16days ago
Latest Ratings for EXEL DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Nov 2021RBC CapitalMaintainsOutperform Nov 2021HC Wainwright & Co.MaintainsBuy View More Analyst Ratings for EXEL View the Latest Analyst Ratings read more...
Business Wire
1month ago
Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-304, a phase 3 pivotal trial evaluating zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced non-clear cell renal cell carcinoma (nccRCC). Zanzalintinib, which was adopted as the generic name...
Business Wire
3 months ago
Exelixis, Inc. (Nasdaq: EXEL) today announced promising initial results from the ongoing dose-escalation stage of JEWEL-101, a phase 1 study evaluating XB002, Exelixis next-generation tissue factor-targeting antibody-drug conjugate. The data are being presented on Friday, October 28 during the...
Frequently Asked Questions
Frequently Asked Questions
What is Exelixis Inc share price today?
plus_minus_icon
Can Indians buy Exelixis Inc shares?
plus_minus_icon
How can I buy Exelixis Inc shares from India?
plus_minus_icon
Can Fractional shares of Exelixis Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Exelixis Inc stocks?
plus_minus_icon
What is today’s traded volume of Exelixis Inc?
plus_minus_icon
What is today’s market capitalisation of Exelixis Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Exelixis Inc?
plus_minus_icon
What percentage is Exelixis Inc down from its 52-Week High?
plus_minus_icon
What percentage is Exelixis Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$17.55
$-0.06
(-0.34%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
NovoCure Limited
NovoCure Limited
$94.22
$-0.87 (-0.91 %)
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc.
$11.58
$-0.42 (-3.50 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$119.00
$-1.25 (-1.04 %)
Neogen Corp
Neogen Corp
$20.29
$-0.81 (-3.84 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
NovoCure Limited
NovoCure Limited
$94.22
$-0.87 (-0.91 %)
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc.
$11.58
$-0.42 (-3.50 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$119.00
$-1.25 (-1.04 %)
Neogen Corp
Neogen Corp
$20.29
$-0.81 (-3.84 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00